BMS Exits HIV R&D by Selling Pipeline to ViiV Healthcare
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2016 Issue 1 (Table of Contents)
Published: 18 Jan-2016
DOI: 10.3833/pdr.v2016.i1.2139 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
With the long-term aim of narrowing the gap on market leader Gilead Sciences, GlaxoSmithKline’s HIV unit ViiV Healthcare, which is minority owned by Pfizer and Shionogi, has agreed to acquire Bristol-Myers Squibb’s clinical-stage and early-stage HIV assets via two separate deals together worth almost US$3 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS